NASDAQ:JUNO Juno Therapeutics (JUNO) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$86.96▼$86.9650-Day Range$86.96▼$86.9652-Week Range$19.62▼$87.01Volume2 shsAverage Volume5.48 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Juno Therapeutics alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Juno Therapeutics Stock (NASDAQ:JUNO)Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.Read More Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. JUNO Stock News HeadlinesApril 9, 2024 | yahoo.comZelda Williams did extensive 'academic study' of '80s films before helming 'Lisa Frankenstein'March 30, 2024 | msn.comMichigan AP names Trey McKenney of Orchard Lake St. Mary's Division 1 basketball Player of the YearJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.March 27, 2024 | finance.yahoo.comXcell Biosciences Announces New Scientific and Business Advisory BoardMarch 18, 2024 | bizjournals.comOut of the lab and into the factoryMarch 16, 2024 | seekingalpha.comEFTR eFFECTOR Therapeutics, Inc.March 15, 2024 | msn.comMotorcyclist killed in fatal accident near Manatee Avenue, Bradenton police sayFebruary 21, 2024 | msn.comWhat we know about Jeff Bezos’ net worthJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.February 8, 2024 | uk.finance.yahoo.comMantle Cell Lymphoma Therapeutics Market to Reach $3.29 Billion by 2028 with Innovations in Targeted TherapiesJanuary 31, 2024 | ca.news.yahoo.comZelda Williams Says She Was 'Fascinated’ by Late Dad Robin Williams' Career from Young AgeJanuary 31, 2024 | msn.comHow Zelda Williams Found Humor in TraumaJanuary 16, 2024 | msn.comCovid cases in Stoke-on-Trent right now as 'Juno' strain hits UKJanuary 11, 2024 | uk.finance.yahoo.comVaginitis Therapeutics Global Market Landscape Analysis 2023-2030: New Treatment Avenues and Key Company Innovations Propel the IndustryJanuary 10, 2024 | finance.yahoo.comAutolus Therapeutics announces the appointment of Robert W. Azelby to its Board of DirectorsJanuary 8, 2024 | tmcnet.comBiotech Industry Veterans Jeff Jonas and Al Robichaud Join Cure Ventures as PartnersJanuary 7, 2024 | seekingalpha.comWeek In Review: 2024 Kicks Off With 3 Deals Worth A Total Of $4BDecember 22, 2023 | msn.comTwo dead in McDermot Avenue fire, cause under investigationSee More Headlines Receive JUNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Juno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2017Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:JUNO CUSIPN/A CIK1594864 Webwww.junotherapeutics.com Phone+1-206-5821600FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesHoward H. Pien (Age 59)Independent Chairman of the Board Hans Edgar Bishop (Age 53)President, Chief Executive Officer, Director Sunil Agarwal M.D. (Age 47)President of Research & Development Steven D. Harr M.D. (Age 46)Chief Financial Officer, Head of Corporate Development Hyam I. Levitsky M.D (Age 54)Executive vice president - Research, chief scientific officer Robert W. Azelby (Age 49)Executive Vice President, Chief Commercial Officer Ann Lee Ph.D.Executive Vice President - Technical OperationsPatrick Y. Yang (Age 69)Executive Vice President Cynthia ElkinsChief Information OfficerBernard J. Cassidy (Age 62)General Counsel, Secretary More Executives JUNO Stock Analysis - Frequently Asked Questions How were Juno Therapeutics' earnings last quarter? Juno Therapeutics Inc (NASDAQ:JUNO) posted its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping analysts' consensus estimates of ($0.80) by $0.07. The business's revenue for the quarter was up 115.4% compared to the same quarter last year. When did Juno Therapeutics IPO? Juno Therapeutics (JUNO) raised $153 million in an initial public offering on Friday, December 19th 2014. The company issued 9,300,000 shares at $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Leerink Partners was co-manager. What other stocks do shareholders of Juno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Juno Therapeutics investors own include (KITE) (KITE), bluebird bio (BLUE), Gilead Sciences (GILD), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN) and TherapeuticsMD (TXMD). This page (NASDAQ:JUNO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Juno Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Juno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
